Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT? (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Sq

- The treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy
- In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of nonsquamous non-small cell lung cancer
- In combination with gemcitabine and platinum chemotherapy, for the first-line treatment of squamous non-small cell lung cancer
- In combination with BYVASDA? (bevacizumab injection) for the first-line treatment of hepatocellular carcinoma
- The second-line treatment of squamous non-small cell lung cancer
Note: |
[1]?The PFS and OS data in China approved indication label for TYVYT? (sintilimab injection). |